Abnova Profile

Abnova is the world's largest antibody manufacturer. We have the capacity of generating 300 mouse monoclonal antibodies and 200 rabbit polyclonal antibodies per month. Rather than the traditional method of antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. We manufacture all our products, recombinant proteins and antibodies in our state-of-the-art production and SPF animal facilities. We also have multiple clones for the monoclonal antibody, and their access is available to partners and collaborators from the academic institutions and industry.




Abnova aims to achieve this using technology specifically developed to enhance both recombinant protein and monoclonal antibody production. Their recombinant protein system is designed to produce proteins using a wheat germ based, cell-free protein synthesis system. This robust and efficient in vitro system translates mrna to target proteins, using a system of wheat germ extract and other essential components. the key advantages of this system are that it produces stable proteins, with good yield, viable structure and physiological functionality.this system in turn forms part of their new approach to raising monoclonal antibodies. the in vitro wheat germ protein expression system provides an effective method for the generation of large quantities of antigens. it also allows the optimisation and automation of key processes, such as improvements for augmenting the mouse antibody response and hybridoma viability, along with customised automation of fusion, subcloning, liquid handling, antibody screening and characterisation. altogether this process provides clones in just 8 weeks.


Using this technology, Abnova have the capacity to generate 500 new mouse monoclonal antibodies each month. Their goal is to have at least one antibody for everygene expressed in the human genome.


The Gap between Genomics and Proteomics


After the completion of human genomic project, most human expressed genes have been identified, and full-length cDNA of these genes have become publicly available. In the emerging proteomics era, proteins act as the key players in the unveiling of these genes. In order to effectively decipher the mystery of these proteins, antibodies with their inherent sensitivity and specificity thus become the most versatile tools for providing one-to-one relationship with their target proteins.


What Abnova Does


The mission of Abnova is to become a leader in high throughput antibody and protein production. Abnova intends to become world's largest protein and antibody catalog company by building a full collection of essential proteins and their antibodies targeting the human genome.


Why Choose Abnova?

Abnova offers a unique complete monoclonal antibody and protein experience for our customer that is different from traditional custom production companies and laboratories.

Industrial-Scale Infrastructure: We maintain a streamlined monoclonal production facility with scalable capacity for up to 500 immunization per month, and a state-of-the-art specific pathogen free (SPF) facility, which has the breeding and holding capacity for 10,000+ mice. These facilities allow us to significantly bring down the cost of customized monoclonal antibody production. We have also incorporated numerous automation systems into our production line, which significantly increased our efficiency.

Wheat Germ In Vitro Protein Expression System: We have a high throughput protein production system, which allows soluble expression of conformational correct protein either from full-length cDNA or specific domains.